Sanofi Revenue 2010-2022 | SNY

Sanofi annual/quarterly revenue history and growth rate from 2010 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Sanofi revenue for the quarter ending September 30, 2022 was $13.233B, a INF% increase year-over-year.
  • Sanofi revenue for the twelve months ending September 30, 2022 was $48.715B, a 49.72% increase year-over-year.
  • Sanofi annual revenue for 2021 was $46.348B, a 8.58% increase from 2020.
  • Sanofi annual revenue for 2020 was $42.687B, a 1.28% increase from 2019.
  • Sanofi annual revenue for 2019 was $42.147B, a 0.03% increase from 2018.
Sanofi Annual Revenue
(Millions of US $)
2021 $46,348
2020 $42,687
2019 $42,147
2018 $42,135
2017 $40,921
2016 $38,408
2015 $38,710
2014 $45,341
2013 $44,240
2012 $46,244
2011 $48,829
2010 $42,539
2009 $42,883
Sanofi Quarterly Revenue
(Millions of US $)
2022-09-30 $13,233
2022-06-30 $11,432
2022-03-31 $11,281
2021-09-30 $12,770
2021-06-30
2021-03-31 $10,713
2020-09-30 $11,548
2020-03-31 $10,277
2019-09-30 $11,032
2019-03-31 $9,896
2018-03-31 $9,988
2017-12-31 $10,572
2017-09-30 $11,040
2017-06-30 $9,828
2017-03-31 $9,482
2016-12-31 $9,904
2016-09-30 $10,373
2016-06-30 $9,385
2016-03-31 $8,746
2015-09-30 $10,770
2015-06-30 $10,466
2014-06-30 $11,175
2013-06-30 $10,560
2012-06-30 $11,716
2012-03-31 $11,247
2011-12-31 $11,701
2011-09-30 $12,087
2011-06-30 $12,061
2011-03-31 $11,423
2010-12-31 $10,075
2010-09-30 $10,788
2010-06-30 $10,648
2010-03-31 $9,748
2009-12-31 $10,098
2009-09-30 $10,922
2009-06-30 $10,582
2009-03-31 $9,190
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $115.062B $44.678B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $463.391B 17.83
Eli Lilly (LLY) United States $347.052B 43.79
AbbVie (ABBV) United States $282.285B 11.70
Pfizer (PFE) United States $276.231B 7.55
Merck (MRK) United States $272.555B 14.03
Novo Nordisk (NVO) Denmark $268.818B 35.25
Novartis AG (NVS) Switzerland $194.067B 14.62